BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 28334978)

  • 1. Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Reeves S; McLachlan E; Bertrand J; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Taylor D; Dunn J; Marsden P; Kessler R; Howard R
    Brain; 2017 Apr; 140(4):1117-1127. PubMed ID: 28334978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease.
    Reeves S; Bertrand J; McLachlan E; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Dunn JT; Marsden P; Kessler R; Uchida H; Taylor D; Howard R
    J Clin Psychiatry; 2017 Jul; 78(7):e844-e851. PubMed ID: 28858444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [18F]fallypride positron emission tomography.
    Clark-Papasavas C; Dunn JT; Greaves S; Mogg A; Gomes R; Brownings S; Liu K; Nwosu B; Marsden P; Joemon J; Cleij M; Kessler R; Howard R; Reeves S
    Int J Geriatr Psychiatry; 2014 Oct; 29(10):1001-9. PubMed ID: 24578318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP).
    Reeves S; Eggleston K; Cort E; McLachlan E; Brownings S; Nair A; Greaves S; Smith A; Dunn J; Marsden P; Kessler R; Taylor D; Bertrand J; Howard R
    Int J Geriatr Psychiatry; 2018 Feb; 33(2):396-404. PubMed ID: 28643852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.
    Vernaleken I; Siessmeier T; Buchholz HG; Härtter S; Hiemke C; Stoeter P; Rösch F; Bartenstein P; Gründer G
    Int J Neuropsychopharmacol; 2004 Dec; 7(4):421-30. PubMed ID: 15683553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
    Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study.
    Meisenzahl EM; Schmitt G; Gründer G; Dresel S; Frodl T; la Fougère C; Scheuerecker J; Schwarz M; Boerner R; Stauss J; Hahn K; Möller HJ
    Pharmacopsychiatry; 2008 Sep; 41(5):169-75. PubMed ID: 18763218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.
    Stone JM; Bressan RA; Erlandsson K; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2005 Aug; 180(4):664-9. PubMed ID: 15719226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
    Vernaleken I; Fellows C; Janouschek H; Bröcheler A; Veselinovic T; Landvogt C; Boy C; Buchholz HG; Spreckelmeyer K; Bartenstein P; Cumming P; Hiemke C; Rösch F; Schäfer W; Wong DF; Gründer G
    J Clin Psychopharmacol; 2008 Dec; 28(6):608-17. PubMed ID: 19011428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.
    Gründer G; Landvogt C; Vernaleken I; Buchholz HG; Ondracek J; Siessmeier T; Härtter S; Schreckenberger M; Stoeter P; Hiemke C; Rösch F; Wong DF; Bartenstein P
    Neuropsychopharmacology; 2006 May; 31(5):1027-35. PubMed ID: 16237387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
    Zipursky RB; Christensen BK; Daskalakis Z; Epstein I; Roy P; Furimsky I; Sanger T; Kapur S
    Can J Psychiatry; 2005 Jul; 50(8):462-9. PubMed ID: 16127964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
    J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
    J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.
    Potkin SG; Keator DB; Kesler-West ML; Nguyen DD; van Erp TG; Mukherjee J; Shah N; Preda A
    CNS Spectr; 2014 Apr; 19(2):176-81. PubMed ID: 24073841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease.
    Reeves S; Bertrand J; D'Antonio F; McLachlan E; Nair A; Brownings S; Greaves S; Smith A; Taylor D; Howard R
    Psychopharmacology (Berl); 2016 Sep; 233(18):3371-81. PubMed ID: 27481049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
    Uchida H; Kapur S; Mulsant BH; Graff-Guerrero A; Pollock BG; Mamo DC
    Am J Geriatr Psychiatry; 2009 Mar; 17(3):255-63. PubMed ID: 19225277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.